DIW Berlin: Thema Wettbewerb und Regulierung

Thema Wettbewerb und Regulierung

319 Ergebnisse, ab 1
Berlin IO Day

The 13th Berlin IO Day (cancelled)

Unfortunately the event is cancelled. As soon as a new date is fixed, it will be announced here on the website. The Berlin IO Day is a one-day workshop sponsored by the Berlin Centre for Consumer Policies (BCCP) and supported by the Berlin's leading academic institutions, including DIW Berlin, ESMT Berlin, Humboldt-Universität zu Berlin, and Technische Universität Berlin. The aim is to

27.03.2020| Rosa Ferrer, Holger Herz, Thomas Otter, Bertel Schjerning, Yossi Spiegel
DIW Applied Micro Seminar

Local News, UGC and Professionals: Evidence from Citizen Journalism (cancelled)

Abstract:  User generated content is increasingly substituting content created by professionals. Local news that is generated by citizen journalists could be a promising way of supporting the struggling newspaper industry by reducing costs for professional journalists. We study a network of 122 local Austrian newspapers operating a hybrid model of citizen and professional journalism. We first

26.03.2020| Jörg Claussen, Ludwig-Maximilians-Universität München
Brown Bag Seminar Cluster Industrial Economics

Market Concentration in Europe: Evidence based on Antitrust Markets (cancelled)

Abstract:  An increasing body of empirical evidence has documented trends to risen concentration, profits, markups, and market power in many industries across the world since the 1980s. Several factors – such as globalisation, digitisation, the increased role of intangible assets and sunk costs, as well as M&A activity and the (under)enforcement of merger control– have been

13.03.2020| Tomaso Duso
Brown Bag Seminar Cluster Industrial Economics

Battling Antibiotic Resistance: Can Machine Learning Improve Prescribing?

Abstract:  Antibiotic misuse due to prescribing under diagnostic uncertainty is a leading driver of antibiotic resistance. We investigate the magnitude and mechanisms by which machine learning predictions can enable policies that reduce antibiotic misuse. Building on predictions from administrative data on urinary tract infections in Denmark, we evaluate counterfactual policies that replace

14.02.2020| Hannes Ullrich
DIW Wochenbericht 3 / 2020

Digitalisierung für das Gemeinwohl: neue Werkzeuge für eine bessere Politik: Kommentar

2020| Tomaso Duso, Hannes Ullrich
Diskussionspapiere 1843 / 2020

Merger Efficiency Gains: Evidence from a Large Transport Merger in France

Many industries are seeing an increase in concentration, leading to a discussion on the effectiveness of horizontal merger enforcement. The policy debate shows that one of the key arguments put forward when supporting potential mergers is the possibility of realization of merger efficiency gains, specifically in the transport industry. Yet, there exists little empirical evidence on the actual

2020| Ariane Charpin, Joanna Piechuka
Zeitungs- und Blogbeiträge

Wettbewerbsfähigkeit 4.0

In: Der Tagesspiegel (03.01.2020), S. 16 | Heike Belitz, Tomaso Duso, Alexander Schiersch
Diskussionspapiere 1851 / 2020

Cost Efficiency and Endogenous Regulatory Choices: Evidence from the Transport Industry in France

We study the impact of different regulatory designs on the cost efficiency of operators providing a public service, exploiting data from the French transport industry. The distinctive feature of the study is that it considers regulatory regimes as endogenously determined choices, explained by economic, political, and institutional variables. Our approach leans on a positive analysis to study the

2020| Joanna Piechucka
Externe referierte Aufsätze

Batteriezellen aus Europa?

In: Wirtschaftsdienst 100 (2020), 1, S. 5 | Heike Belitz, Martin Gornig
Brown Bag Seminar Cluster Industrial Economics

Determinants of Ownership Changes in the Market for Diabetes

Abstract:  This paper investigates the determinants of ownership changes of drug candidates in one of the most important current pharma markets —the market for diabetes. We in particular look at how do the competitive circumstances, progress in clinical development and radicalness of the drug candidates matter in these decisions. We use newly constructed, very granular dataset tracking

20.12.2019| Jan Malek
319 Ergebnisse, ab 1